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To harness the immune system’s cytotoxic capacity to
fight solid tumors, we developed tetravalent, bifunctional
antibodies that recognize EGFRvIII, the deletion variant III
of EGFR, and either CD3 or CD16A on immune cells,
thereby directing T cells or NK-cells to eliminate EGFR-
vIII+ cancer cells.
Using phage display, we identified scFv antibodies that
selectively bind to EGFRvIII. These highly EGFRvIII-
specific scFv antibodies were substantially improved by
affinity maturation achieving KDs in the 100 pM range
or lower and used to construct a set of bispecific EGFR-
vIII-targeting TandAbs with a broad range of binding
and cytotoxic properties. Mono- and bivalent binding
constants, specificity for EGFRvIII and CD3 or CD16A,
cytotoxic activity, and target-dependent effector cell
activation were characterized in a panel of in vitro
assays. TandAbs exhibited exquisite specificity towards
the EGFRvIII antigen in Western Blot, SPR, ELISA, and
FACS assays of EGFRvIII+ cells. No binding was
observed to recombinant EGFR or to EGFR+ cells. The
TandAbs apparent affinities for EGFRvIII were up to
25-fold improved relative to the monovalently binding
scFvs, resulting in a KD of 11 pM for the best TandAb.
EGFRvIII/CD3 and EGFRvIII/CD16A TandAbs with
high affinity for EGFRvIII were similarly potent in killing
assays, displaying cytotoxicity towards EGFRvIII+ F98
glioma, transfected CHO or human DKMG cells with
EC50 in the range of 1 pM – 10 pM. No cytotoxicity was
observed on EGFR+ cells or EGFRvIII-negative cells
demonstrating the high selectivity of EGFRvIII TandAbs
for the tumor-specific EGFRvIII. Importantly, in the
absence of EGFRvIII+ target cells in vitro TandAbs did not
elicit T- or NK-cell activation, as demonstrated by their
lack of proliferation. Binding to EGFRvIII in different solid
tumor types and its absence from healthy tissues was
shown by immunohistochemistry using a high affinity
EGFRvIII-binding bivalent Diabody.
In summary, EGFRvIII/CD3 and EGFRvIII/CD16A
TandAbs provide an opportunity to develop cytotoxic
antibodies that solely target cancer, sparing normal tis-
sues and thereby reduce the side effects associated
with EGFR therapy.
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